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ANALYSIS OF DRUG INTERACTIONS WITH MODIFIED
PROTEINS BY HIGH-PERFORMANCE AFFINITY
CHROMATOGRAPHY: BINDING OF GLIBENCLAMIDE TO
NORMAL AND GLYCATED HUMAN SERUM ALBUMIN
Ryan Matsuda, Jeanethe Anguizola, K.S. Joseph, and David S. Hage*
Department of Chemistry, University of Nebraska-Lincoln, Lincoln, NE 68588-0304 (USA)
Abstract
High-performance affinity chromatography (HPAC) was used to examine the changes in binding
that occur for the sulfonylurea drug glibenclamide with human serum albumin (HSA) at various
stages of glycation for HSA. Frontal analysis on columns containing normal HSA or glycated
HSA indicated glibenclamide was interacting through both high affinity sites (association
equilibrium constant, Ka, 1.4–1.9 × 106 M−1 at pH 7.4 and 37°C) and lower affinity sites (Ka, 4.4–
7.2 × 104 M−1). Competition studies were used to examine the effect of glycation at specific
binding sites of HSA. An increase in affinity of 1.7- to 1.9-fold was seen at Sudlow site I with
moderate to high levels of glycation. An even larger increase of 4.3- to 6.0-fold in affinity was
noted at Sudlow site II for all of the tested samples of glycated HSA. A slight decrease in affinity
may have occurred at the digitoxin site, but this change was not significant for any individual
glycated HSA sample. These results illustrate how HPAC can be used as tool for examining the
interactions of relatively non-polar drugs like glibenclamide with modified proteins and should
lead to a more complete understanding of how glycation can alter the binding of drugs in blood.
Keywords
High-performance affinity chromatography; Drug-protein binding; Glibenclamide; Human serum
albumin; Glycation
1 Introduction
The International Diabetes Federation reported in 2011 that 366.2 million people in the
world are affected by diabetes [1]. A total of 25.8 million are affected by diabetes in the
United States alone [2]. Diabetes is a condition that is caused by high glucose levels in blood
and has two major forms [3]. Type I diabetes (i.e., juvenile onset or insulin-dependent
diabetes) affects 5–10% of diabetic patients and is caused when pancreatic beta cells (i.e.,
insulin-producing cells) are attacked by the immune system [2]. Most of the remaining 90–
95% of diabetic patients suffer from type II diabetes (i.e., non-insulin dependent or adult
onset diabetes), which is caused by insulin resistance [1,2].
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Sulfonylurea drugs are oral medications that are commonly used to treat type II diabetes.
These drugs lower blood glucose levels by increasing the amount of insulin that is produced
by pancreatic beta cells [4]. According to the biopharmaceutical classification system,
sulfonylurea drugs are listed as class II drugs with high permeability and low solubility [5].
Figure 1 shows the core structure of a sulfonylurea drug, which is composed of
phenylsulfonyl and urea groups, both which are hydrophilic [6,7]. Various non-polar
functional groups can be found on either side of this core structure and contribute to both the
effectiveness and metabolism of these drugs [6–8]. Glibenclamide, or glyburide (see Figure
1), is a popular second-generation sulfonylurea drug. Second-generation sulfonylurea drugs
like glibenclamide are more easily excreted and can be prescribed in lower doses than first-
generation sulfonylureas (e.g., tolbutamide and acetohexamide) [8]. For instance,
glibenclamide has a therapeutic level in serum of 0.08–0.4 μM versus 60–215 or 185–370
μM for acetohexamide and tolbutamide, respectively [9].
Although sulfonylurea drugs are used to lower blood glucose levels, hypoglycemia is a
relatively common side effect if the apparent dose of these drugs is too high. This situation
occurs in 2%–20% of patients, depending on the type of sulfonylurea being used [10]. One
factor that will affect the free fractions of these drugs in the circulation, and their apparent
dose, is the level of binding by these drugs with serum proteins, especially with human
serum albumin (HSA) [6,9–12]. HSA (molar mass, 66.5 kDa) is the most abundant protein
in plasma and is responsible for transporting various fatty acids, low mass hormones, and
drugs in the circulation [11–19]. There are two main drug binding sites on HSA: Sudlow
sites I and II. Sudlow site I is found in subdomain IIA and binds to bulky heterocyclic
anionic drugs such as warfarin, azapropazone, phenylbutazone and salicylate [12,13].
Sudlow site II is located in subdomain IIIA and can bind to ibuprofen, fenoprofen,
ketoprofen, benzodiazepine, and L-tryptophan, among other solutes [12,13]. Recent studies
have shown that both of these sites have interactions with first-generation sulfonylurea
drugs, tolbutamide and acetohexamide, and the second-generation drug gliclazide [14–16].
Other studies have found that some drugs can bind to a separate region on HSA known as
the digitoxin site [17–22], but no previous reports have examined the interactions of
sulfonylureas at this site.
The elevated levels of glucose in blood during diabetes can lead to a protein modification
known as glycation [23–28]. Glycation is a non-enzymatic process in which amine groups
can undergo the formation of a reversible Schiff base with the open chain form of a reducing
sugar. The Schiff base can later rearrange to form a more stable Amadori product. Patients
with diabetes are estimated to have 20–30% or more of HSA in a glycated form, while
individuals without diabetes may have 6–13% of HSA glycated [23,24,26]. Previous work
has suggested that glycation can alter the interactions between HSA and some solutes. For
instance, it has been shown in chromatographic studies that glycation can alter the ability of
Sudlow sites I and II on HSA to bind with sulfonylurea drugs [14–16]. Experiments based
on fluorescence spectroscopy, circular dichroism, and theoretical calculations have also
found that glycation and related modifications can affect intermolecular interactions
between drugs and HSA, including possible changes in the binding of drugs at Sudlow site I
of this protein [29,30].
The purpose of this study is to use high-performance affinity chromatography (HPAC) to
examine the binding of glibenclamide to HSA at various stages of glycation. HPAC is a
chromatographic technique that uses an immobilized biological molecule as the stationary
phase [31–33]. Previous studies have shown that columns containing normal HSA or
glycated HSA can provide good precision and fast analysis times for studies of drug-protein
interactions [14–16], while also giving good correlation with solution-based methods (e.g.,
equilibrium dialysis, ultrafiltration, or spectroscopic methods) [32,33]. In addition, HPAC is
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easy to automate and can be used with various detection schemes, including absorbance,
fluorescence or mass spectrometry [31–38]. HPAC has been used previously in detailed
studies that have examined the effects of glycation on the binding of HSA to other
sulfonylurea drugs [14–16], as well as the effects of some specific modifications on drug-
protein interactions (e.g., the selective modification of Tyr-411, Trp-214, or Cys-34 on
HSA) [39–41]. However, this approach has only been used in screening studies with
glibenclamide and required a solubilizing agent for work with this relatively low solubility
drug [42]. These conditions and the lack of more complete binding information have, in
turn, made it difficult in prior work to directly compare the overall interactions of HSA with
this drug and with other sulfonylureas.
This report will seek to overcome these prior limitations by examining how HPAC can be
adapted for providing more complete information on the protein binding of relatively low
solubility drugs such as glibenclamide. For instance, this approach will be modified and
explored for use with such a drug in the methods of frontal analysis and zonal elution to look
at both the global and site-specific changes in binding that may occur for glibenclamide with
normal HSA versus in vitro glycated HSA. These experiments should help indicate how
HPAC can then be modified for use with other non-polar drugs. In addition, this work
should provide useful data on how glycation can alter the binding of glibenclamide or
related drugs to HSA and lead to a more complete understanding of how glycation can alter
the binding and transport of such drugs in the circulation.
2 Experimental
2.1 Reagents
The glibenclamide (≥ 99.9% pure), R-warfarin (≥ 97%), L-tryptophan (≥ 97%), digitoxin
(97% pure), β-cyclodextrin (> 98% pure), D-(+)-glucose (≥ 99.5%), sodium azide (95%),
HSA (essentially fatty acid free, ≥ 96%), and commercial sample of in vitro glycated HSA
(Lot 058K6087) were obtained from Sigma-Aldrich (St. Louis, MO, USA). The Nucleosil
Si-300 (7 μm particle diameter, 300 Å pore size) was purchased from Macherey-Nagel
(Düren, Germany). Reagents for the bicinchoninic acid (BCA) protein assay were from
Pierce (Rockford, IL, USA). For the measurement of glycation levels, a fructosamine assay
kit was obtained from Diazyme Laboratories (San Diego, CA, USA). All aqueous solutions
were prepared with water from a Nanopure system (Barnstead, Dubuque, IA, USA) and
filtered through a 0.2 μm GNWP nylon membrane from Millipore (Billerica, MA, USA).
2.2 Apparatus
The chromatographic system was comprised of a DC-2080 degasser, two PU-2080 pumps,
an AS-2057 autosampler, a CO-2060 column oven, and a UV-2075 absorbance detector
from Jasco (Tokyo, Japan), which included a Rheodyne Advantage PF six-port valve
(Cotati, CA, USA). EZ Chrom Elite software v3.21 (Scientific Software, Pleasanton, CA,
USA) and Jasco LC Net were used to control the system. Chromatograms were analyzed
through the use of Peak-Fit 4.12 (Jandel Scientific Software, San Rafael, CA, USA). Data
Fit 8.1.69 (Oakdale, PA, USA) was utilized to perform non-linear regression.
2.3 Methods
For the sake of comparison, the in vitro glycated HSA samples used in this work were the
same as employed in previous HPAC studies with other sulfonylurea drugs [14–16,43].
Although many prior studies have used in vitro glycated HSA for binding studies like those
described in this report [14–16,30,44], it has also been suggested in recent work with related
modifications that in vivo glycated HSA may provide a better model for representing drug-
protein interactions that occur at physiological conditions [44]. To minimize differences due
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to the use of in vitro glycated HSA in this study, conditions for preparation of the glycated
HSA samples were selected to closely mimic the glucose and protein concentrations and
reaction conditions that are present in blood. The gHSA1 was purchased from Sigma and
was glycated under proprietary conditions; this support had a measured glycation level of
1.31 (± 0.05) mol hexose/mol HSA, as might be found in a patient with prediabetes, and
represented mildly glycated HSA [14–16,43]. The gHSA2 and gHSA3 samples were
prepared in vitro as described previously [14,15,43] and represented glycation levels of
patients with controlled or advanced diabetes [45,46]. These two preparations contained
2.34 (± 0.13) and 3.35 (± 0.14) mol hexose/mol HSA, respectively [14,15]. It has been
found in separate, ongoing studies based on mass spectrometry and ultrafiltration and HPAC
that these protein preparations have similar modification patterns and binding properties to
samples of in vivo HSA with comparable levels of glycation [47–51], thus making these
preparations reasonable models for the types of binding studies that are described in this
report.
Diol-bonded silica was produced from Nucleosil Si-300 silica according to the literature
[52]. The Schiff base method was used to immobilize HSA or glycated HSA onto the diol-
bonded silica, also as reported previously [53–55]. Using the same procedure, control
supports were prepared with no protein being added during the immobilization step.
Although both the Schiff base immobilization method and glycation involve free amine
groups on proteins, these processes tend to involve different residues on HSA [49–51]. A
BCA assay was carried out in triplicate to determine the protein content of each support,
using soluble HSA as the standard and samples containing the control support as the blanks.
The support containing normal HSA was found previously with this assay to have a protein
content of 38 (± 3) mg HSA/g silica. The three types of glycated HSA supports that were
prepared (referred to later in this report as gHSA1, gHSA2 and gHSA3) were found to have
protein contents of 29 (± 4), 47 (± 8), or 40 (± 3) mg HSA/g silica [14,43].
All of the supports were downward slurry packed into separate 2.0 cm × 2.1 mm I.D.
columns at 3500 psi (24 MPa) using pH 7.4, 0.067 M potassium phosphate buffer. These
columns were then stored at 4°C in the same pH 7.4 phosphate buffer. Each column was
used in fewer than 500 sample applications and was routinely washed with pH 7.4, 0.067 M
phosphate buffer. Throughout the course of this study, no significant changes in binding
properties were noted for any of these columns, as reported previously for similar systems
[53].
The R-warfarin, L-tryptophan, glibenclamide and digitoxin samples were prepared in pH
7.4, 0.067 M potassium phosphate buffer. The limited solubility of digitoxin (i.e., roughly 4
mg/L) [56] required the addition of 0.88 mM β-cyclodextrin to increase the solubility of this
drug, as described in prior work [20–22]. The R-warfarin and digitoxin solutions were used
within two weeks of preparation, and the L-tryptophan solutions were used within one day
of preparation, respectively [43,57]. Due to the low solubility of glibenclamide in water, the
procedure for preparing solutions containing this drug were altered from those used in
previous studies with other, more soluble sulfonylurea drugs. Previous HPAC studies with
acetohexamide, tolbutamide and gliclazide could be carried out by preparing overnight, with
stirring at room temperature, solutions that contained up to 200–1000 μM of these drugs in a
pH 7.4, 0.067 M phosphate buffer [14–16]. Glibenclamide was much less soluble under the
same conditions and additional steps had to be taken to provide a suitably broad range of
concentrations for use in methods such as frontal analysis. β-Cyclodextrin has previously
been employed as a solubilizing agent for glibenclamide in screening studies [42]; however,
this approach alters the apparent retention of the applied drug onto the column and requires
relatively complex procedures to correct for this effect and carry out more detailed binding
studies [31–38]. In this current study, solutions of glibenclamide were instead prepared
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without the use of any solubilizing agent by utilizing both stirring and sonication in a
covered container that was kept for 5–7 days at 35–50°C. It was found that a stable stock
solution containing up to 50 μM glibenclamide could be prepared under these conditions, as
confirmed by absorbance measurements and dilution studies. This stock solution was then
used directly or diluted to make working solutions for frontal analysis and zonal elution
experiments involving HPAC.
The mobile phases used in the chromatographic studies were based on pH 7.4, 0.067 M
potassium phosphate buffer, which was used to apply the samples and to elute retained
analytes under isocratic conditions. The solutions used in the chromatographic system were
filtered through a 0.2 μm nylon filter and were degassed for 10–15 min before use. All
experiments were carried out at a physiological temperature of 37°C and using a flow rate of
0.5 mL/min. Prior work on similar columns has shown that frontal analysis and zonal elution
studies performed under these flow rate conditions allow for the reproducible measurements
of retention factors, binding capacities, and association equilibrium constants [14–
16,43,55,57].
In the frontal analysis experiments, the columns were first equilibrated with pH 7.4, 0.067 M
potassium phosphate buffer. Using a six-port valve, a switch was made from this pH 7.4
buffer to a solution containing a known concentration of glibenclamide in the same buffer.
After a breakthrough curve was formed and a stable plateau had been reached, a switch was
made back to the pH 7.4, 0.067 M potassium phosphate buffer to elute the retained drug.
These frontal analysis experiments were carried out using sixteen sample solutions that
contained 1–50 μM glibenclamide, with the elution of glibenclamide being monitored at 250
nm. All experiments were performed in quadruplicate and the central point of each
breakthrough curve was determined by using the equal area function of Peak Fit 4.12. A
correction for non-specific binding (e.g., 41% of the total binding seen on the HSA column
for 50 μM glibenclamide) was made by subtracting the results for the control column from
the data for each column containing normal HSA or glycated HSA, according to methods
described in Refs. [14,16].
The zonal elution competition studies were carried out by utilizing R-warfarin as a site-
specific probe for Sudlow site I of HSA, L-tryptophan as a probe for Sudlow site II, and
digitoxin as a probe for the digitoxin site [12,13,20–22]. Mobile phases containing 1–20 μM
glibenclamide were used in these experiments. These concentrations were used to dilute the
site-specific probes to a concentration of 5 μM. During these studies, a 20 μL sample of 5
μM R-warfarin, L-tryptophan and digitoxin was injected onto each column and monitored at
308 nm, 280 nm, or 205 nm, respectively. Sodium nitrate, which was monitored at 205 nm,
was injected at a concentration of 20 μM and used as a non-retained solute [32,38,42,43].
All of these injections were performed in quadruplicate on each protein column or control
column. The central moments for the resulting peaks were determined by using PeakFit
v4.12 and an exponentially modified Gaussian curve model.
3. Results and Discussion
3.1 Frontal analysis studies
Frontal analysis was used to first examine the overall binding of glibenclamide to the normal
HSA and glycated HSA columns. These experiments used HPAC to examine the global
binding of glibenclamide with these proteins by providing information on the number of
binding sites and association equilibrium constants for these sites. Figure 2 shows some
typical breakthrough curves that were produced in these studies, which typically required 5–
20 min to obtain. The moles of drug that were required to reach the central point of each
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breakthrough curve were measured as a function of the concentration of the applied drug.
The results were then fit to various binding models.
Eqs. (1) or (2) were used to see how such data agreed with a model that involved the
interactions of glibenclamide at a single type of binding region on HSA or glycated HSA
[32,38].
One-site model:
(1)
(2)
In these equations, the term mLapp represents the measured moles of applied drug that was
required to reach the central point of the breakthrough curve at a given molar concentration
of the applied drug, [A] [32,38]. The association equilibrium constant and total moles of
binding sites for this interaction are represented by terms Ka1 and mL1, respectively.
A two-site binding model was also used to examine the data, as described by Eqs. (3) and
(4) [32,38].
Two-site model:
(3)
(4)
In these equations, Ka1 and Ka2 represent the association equilibrium constants for the two
classes of sites, while the moles of these two groups of sites are described by the terms mL1
and mL2. Eq. (4) also includes the term α1, which represents the fraction of all binding sites
for the drug that are made up of its highest affinity regions (e.g., α1 = mL1/mLtot if Ka1 and
mL1 are used to refer to the highest affinity sites). In a similar manner, the ratio of the
association equilibrium constants for the low versus high affinity sites is represented by β2,
where β2 = Ka2/Ka1 in the case where Ka1 refers to the highest affinity sites and Ka2 refers
to the lower affinity sites [32,38].
Previous results with other sulfonylurea drugs have indicated that these solutes tend to
follow a two-site binding model during their interactions with both normal HSA and
glycated HSA [14–16,58]. Figure 3 shows the results that were obtained when using non-
linear regression and the non-transformed data from a frontal analysis experiment with
glibenclamide and the normal HSA column; similar trends were seen for glycated HSA. In
each case, lower concentrations were used in this work with glibenclamide than in previous
experiments with other sulfonylurea drugs [14–16] due to the lower solubility of
glibenclamide in an aqueous solution. To help compensate for this lower range and provide
good estimates of the binding parameters for the system, a greater number of concentrations
were tested in the given range and more replicates were used at each concentration (e.g.,
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sixteen tested concentrations versus nine to fifteen and four replicates versus three for most
of the previous experiments in Refs. [14–16]). Furthermore, several samples were at the
lower end of this concentration range to better examine the stronger binding that was
observed for glibenclamide with HSA when compared with previously-examined
sulfonylureas [14–16]. Under these conditions, a two-site binding model was again found to
give a better fit than a one-site binding model for the glibenclamide data in Figure 3, with a
correlation value of 0.997 (n = 16) versus 0.952, respectively. As shown by the insets to
Figure 3, residual plots for the two-site model gave a more random distribution of the
residuals about the best-fit line when compared to the results for the one-site model and a
smaller sum of the squares of the residuals (i.e., 3.0 × 10−18 vs. 4.9 × 10−17).
The presence of more than one group of binding sites for glibenclamide on normal HSA was
confirmed when using Eqs. (2) and (4) and a double reciprocal plot of 1/mLapp vs. 1/[A] as
an alternative route to examine the data. When this type of plot was made (see Figure 4), a
linear relationship was seen as the value of 1/[A] increased, with clear deviations being
noted at smaller values of 1/[A]. If one-site binding were present, a linear response at all
values of 1/[A] would have been expected in such a plot, as predicted by Eq. (2). The fact
that deviations from linearity were seen at small values for 1/[A] meant that at least two
groups of sites were involved in this interaction, as indicated by Eq. (4) (note: similar
deviations from linearity are expected for higher-order binding models) [32,38]. The linear
response that was noted at higher values of 1/[A] in Figure 4 is predicted even for models
involving multiple binding sites, as shown by Eq. (5) [59,60].
(5)
In addition, it is known from this linear region that an estimate can be made for the
association equilibrium constant of the highest affinity sites in the column [59,60]. Using the
linear region of Figure 4, the value of Ka1 was found to be approximately 6.4 (± 0.5) × 105
M−1 for the normal HSA column, where the value in parentheses represents a range of ± 1
S.D. This value for Ka1 is comparable to a binding constant of 7.6 × 105 M−1 at 37°C and
pH 7.4 that has been previously reported for glibenclamide with normal HSA when using a
one-site binding model [61].
Use of the two-site model in Eq. (3) and the non-transformed frontal analysis data provided
association equilibrium constants of 1.4 (± 0.5) × 106 M−1 and 4.4 (± 1.0) × 104 M−1 for the
binding of normal HSA with glibenclamide at pH 7.4 and 37°C (see Table 1). The mL
values for these sites were 1.1 (± 0.2) × 10−8 mol and 3.1 (± 0.1) × 10−8 mol, respectively,
in the column that was used for this experiment. It was noted in this case that the result for
Ka1 was roughly 10-fold higher than the corresponding values for the high affinity sites that
have been measured on an identical column and under the same mobile phase conditions for
other sulfonylurea drugs (i.e., tolbutamide, acetohexamide and gliclazide) [16,58] (Note: a
lower retention for glibenclamide on an HSA column was noted versus these other drugs in
the screening studies described in Ref. [42], but in this earlier case the apparent retention for
glibenclamide was lowered by the presence of β-cyclodextrin as a solubilizing agent). An
increase in affinity for glibenclamide to HSA when compared to first-generation
sulfonylurea drugs has been noted previously and was expected due to the larger aromatic
groups that are present in glibenclamide versus these other agents [61].
The specific activity based on the protein content for this column at the high and lower
affinity sites were 0.63 (± 0.09) and 1.73 (± 0.07) mol/mol normal HSA, respectively. This
result suggested that one high affinity region existed on HSA with a binding constant in the
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range of 106 M−1, along with several lower affinity regions with binding constants between
104 and 105 M−1. For comparison, analysis of the same data by using a one-site model
resulted in an intermediate value for Ka1 of 2.0 (± 0.3) × 105 M−1, a value for mL1 of 3.3 (±
0.1) × 10−8 mol, and a relative activity of 1.8 (± 0.1) mol/mol normal HSA.
Frontal analysis experiments were also performed with glibenclamide and a highly glycated
HSA sample (gHSA3). Plots prepared according to Eqs. (1–4) gave trends similar to those
shown for normal HSA in Figures 3 and 4. For each type of plot, the glycated HSA column
again gave the best-fit to a two-site model (see summary in Table 1). The one-site model
gave a correlation coefficient of 0.976 (n = 16) in comparison to a correlation coefficient of
0.994 for a two-site model for this column. Residual plot analysis for the two different
models showed a random distribution for the two-site model and a smaller sum of the
squares of the residuals when compared to the one-site model (i.e., 8.5 × 10−18 vs. 3.7 ×
10−17). The association equilibrium constants obtained for this column when using Eq. (3)
and a two-site model were 1.9 (± 1.5) × 106 M−1 and 7.2 (± 2.8) × 104 M−1. Based on the
measured levels of these sites and the column’s known protein content, the relative activities
for these sites were found to be 0.45 (± 0.16) and 1.20 (± 0.11) mol/mol gHSA3, which were
consistent with the results observed for normal HSA. Analysis of the same data according to
a double reciprocal plot gave deviations from linearity that confirmed at least two groups of
binding sites were present. The linear region of this latter plot was again used with Eq. (5) to
estimate Ka1 for the high affinity sites, giving a value of 6.8 (± 0.4) × 105 M−1. This result
was comparable to the binding constant that was estimated by the same approach for the
high affinity sites of glibenclamide with normal HSA.
3.2 Binding of glibenclamide at Sudlow site I
Competition studies and zonal elution were next used to test for any changes that may have
occurred in the binding of glibenclamide at specific binding sites on normal HSA or
glycated HSA. These experiments used site-specific probes to examine the competition
between the injected probe and a competing agent, such as a drug that was placed at a
known concentration in the mobile phase. R-Warfarin was employed as a site-specific probe
for Sudlow site I in these studies, while the mobile phase contained glibenclamide as a
competing agent. Sudlow site I was of interest in this work because previous studies with
other sulfonylurea drugs have shown that this region has a relatively high affinity for these
solutes on both normal HSA and glycated HSA [14–16,58]. Examples of some results that
were obtained in this report with glibenclamide are given in Figure 5(a). In both these zonal
elution studies and those described in the following sections, the same range in
concentrations for glibenclamide as a competing agent was used as in prior work with other
sulfonylurea drugs [14–16,58] because this range was well within the solubility limit of
glibenclamide. However, the number of concentrations that were tested in this range was
increased (from five-to-six up to seven-to-eight) and the number of replicates was increased
(from three to four) to allow for more precise estimates to be obtained for the binding
parameters of this system.
When analyzing data like that given in Figure 5, direct competition between an injected site-
specific probe and a competing agent for a common binding site on an immobilized protein
should result in a decrease in the retention factor (k) for the probe as the molar concentration
of the competing agent ([I]) is increased [15,32]. The change in k as a function of [I] for a
system with competition at a single type of site is described by Eq. (6). This equation
predicts that a linear relationship will be formed for such a system when a plot is made of 1/
k versus [I].
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(6)
In this equation, KaA and KaI are the association equilibrium constants for the injected probe
and competing agent, respectively, at their site of competition. The term VM is the column
void volume, and mL represents the moles of common binding sites in the column.
According to this relationship, the ratio of the slope to the intercept for the best-fit line can
be used to find KaI, which provides information on the association equilibrium constant for
the agent in the mobile phase at its specific site of competition with the injected probe.
Examination of the specific changes in binding at Sudlow site I for glibenclamide by this
approach gave linear relationships according to Eq. (6) for the columns that contained either
normal HSA or glycated HSA and under the drug concentrations that could be employed in
these studies. These lines had correlation coefficients that ranged from 0.966 to 0.992 (n =
6–8). Residual plots gave random distributions for the data about the best-fit lines and sums
for the squares of the residuals that ranged from 2.9 × 10−7 to 2.3 × 10−5. The results for all
the tested columns were found to fit with a direct competition model for glibenclamide and
R-warfarin at Sudlow site I. Similar previous experiments have noted that related drugs such
as tolbutamide, acetohexamide and gliclazide also bind to this site on HSA [14–16].
In the next stage of this work, the association equilibrium constants that were obtained from
Eq. (6) were used to see how the binding of glibenclamide at Sudlow site I was affected as
the level of glycation for HSA was varied. The results are summarized in Table 2. The site-
specific association equilibrium constant that was measured by this approach for
glibenclamide at Sudlow site I of normal HSA was 2.4 (± 0.3) × 104 M−1 at pH 7.4 and
37°C. This value was slightly smaller than association equilibrium constants of 4.2–5.5 ×
104 M−1 that have been reported for normal HSA with the first-generation sulfonylurea
drugs tolbutamide and acetohexamide but was similar to an association equilibrium constant
of 1.9 × 104 M−1 that has been measured at this site for gliclazide, another second-
generation sulfonylurea drug [14–16,58] This binding constant is lower than the values of
0.64–1.4 × 106 M−1 which were estimated in Section 3.1 for the high affinity sites of
glibenclamide with normal HSA, indicating that other regions probably made up the high
affinity sites for this drug. It was further noted that this affinity was in the same general
range as the value of 4.4 (± 1.0) × 104 M−1 that was obtained in Section 3.1 for the lower
affinity sites of glibenclamide with normal HSA.
The association equilibrium constant for glibenclamide at Sudlow site I for normal HSA was
next compared to values measured at the same site for each glycated HSA sample. There
was no significant increase in the association equilibrium constant for glibenclamide at
Sudlow site I in going from normal HSA to gHSA1. However, a 1.7- to 1.9-fold increase in
the association equilibrium constant was noted between normal HSA and gHSA2 or gHSA3,
which was significant at the 95% confidence level. A change in affinity with the level of
glycation has also been observed at Sudlow site I for tolbutamide, acetohexamide, and
gliclazide [14–16], as well as for other drugs (e.g., meloxicam and warfarin) [30]. These
changes have been suggested to be due to variations in the extent and types of modifications
that occur at Sudlow site I during the glycation process [14–16,30,49–51].
3.3 Binding of glibenclamide at Sudlow siteII
Competition experiments were also performed for glibenclamide using L-tryptophan as a
probe for Sudlow site II of HSA. Previous studies have shown that this site is another region
that has moderately strong binding to other sulfonylurea drugs [14–16,58]. Figure 5(b)
shows some examples of the data that were obtained for normal HSA and glycated HSA in
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these experiments. All of the results gave a linear responses when fit to Eq. (6), with
correlation coefficients that ranged from 0.968 to 0.993 (n = 7–8). The corresponding
residual plots gave a random distribution of the points about the best-fit lines. It was
determined from these results that glibenclamide was competing with L-tryptophan and was
binding directly to Sudlow site II on both normal HSA and glycated HSA.
The site-specific association equilibrium constants that were determined for glibenclamide
at Sudlow site II through these competition studies are summarized in Table 2. The affinity
for glibenclamide at Sudlow site II of normal HSA was 3.9 (± 0.2) × 104 M−1, which is
similar to values of 5.3–13 × 104 M−1 that have been reported at this site for acetohexamide,
tolbutamide and gliclazide [14–16,58]. However, this result is still much lower than the high
affinity constant of 0.64–1.4 × 106 M−1 that was estimated for glibenclamide with HSA in
Section 3.1. Thus, this indicated that another region on this protein besides Sudlow sites I or
II also had strong interactions with glibenclamide. The binding constant for glibenclamide to
Sudlow site II of normal HSA was instead a better fit with the value of 4.4 (± 1.0) × 104
M−1 that was measured in the frontal analysis studies for the lower affinity regions of HSA.
This similarity, when combined with the results in Section 3.2 and the moles of low affinity
regions that were determined in Section 3.1, suggested that both Sudlow sites I and II made
up the lower affinity sites that were detected during the frontal analysis experiments. This
model also fits with the observation that the value for Ka2 in Table 1 increased significantly
in going from normal HSA to gHSA3, because a large increase was also seen in Table 2 for
the association equilibrium constant of glibenclamide at Sudlow site II between normal HSA
and gHSA3.
Table 2 shows how the affinity for glibenclamide with HSA at Sudlow site II, as determined
from the best-fit lines obtained with Eq. (6), changed as the level of glycation for HSA was
increased. The columns containing gHSA1, gHSA2 and gHSA3 had a 4.3-, 6.0- or 4.6-fold
increase in affinity for glibenclamide at Sudlow site II versus normal HSA. All of these
differences were significant at the 95% confidence level. This trend is similar to the large
increases in affinity that have been observed for L-tryptophan with the same samples of
glycated HSA [62]. Tolbutamide has also been noted to have a modest increase in affinity at
this site during the glycation of HSA [15], while acetohexamide and gliclazide have been
found to have a moderate decrease in affinity or a mixed change in binding strength as the
levels of glycation for HSA are varied [14,16].
3.4 Binding of glibenclamide at the digitoxin site
To help locate the high affinity region for glibenclamide on HSA, digitoxin was also used as
a site-specific probe for HSA [17–22]. Figure 6 provides some typical results that were
obtained for normal HSA and glycated HSA. When Eq. (6) was used to analyze these
results, all of the normal and glycated HSA columns gave a linear response. The best-fit
lines had correlation coefficients that ranged from 0.994 to 0.999 (n = 4–5), and the residual
plots gave a random distribution for the data about the best-fit lines. These results indicated
that glibenclamide and digitoxin had direct competition on the tested columns, confirming
that glibenclamide was binding to the digitoxin site of HSA. This result is supported by a
previous observation that glibenclamide and first-generation drugs such as tolbutamide
appear to bind to different numbers of sites and through different mechanisms with HSA,
with non-polar interactions being important for glibenclamide and ionic forces playing a
greater role for tolbutamide [61]. This model and the observed binding of glibenclamide to
the digitoxin site is also consistent with the fact that this site is known to bind other large,
relatively hydrophobic drugs such as digitoxin and acetyldigitoxin [17–22].
The association equilibrium constants for glibenclamide at the digitoxin site were next
calculated from the best-fit lines of plots like those in Figure 6. The results are summarized
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in Table 2. In this case, the association equilibrium constant measured for glibenclamide at
the digitoxin site of normal HSA was 2.1 (± 0.8) × 106 M−1. This value was now statistically
identical to the association equilibrium constant of 1.4 (± 0.5) × 106 M−1 that had been
previously estimated by frontal analysis for the high affinity sites of glibenclamide on
normal HSA. The same group of experiments suggested that there may have been a decrease
of 1.2- to 1.9-fold in affinity at the digitoxin site for glibenclamide when going from normal
HSA to gHSA1, gHSA2 or gHSA3. None of these individual differences were significant at
the 90% or 95% confidence level; however, the overall trend of a decrease in affinity with
an increase in the level of HSA glycation was significant at the 90% confidence level when
the complete set of samples was considered.
4 Conclusion
This report illustrated how HPAC could be modified for use with relatively low solubility
drugs such as glibenclamide and used as a tool to examine variations in drug interactions
with modified proteins, as demonstrated by using this approach to investigate the changes
that occur in the binding of glibenclamide to HSA at various stages of glycation. Frontal
analysis studies were used to estimate the affinity and moles of binding sites for
glibenclamide with HSA. The results showed that binding with normal HSA and glycated
HSA followed a two-site model in which interactions occurred at both high and lower
affinity sites. The association equilibrium constants for the high affinity regions were in the
range of 1.4–1.9 × 106 M−1 at pH 7.4 and 37°C for columns containing normal HSA or
glycated HSA. The lower affinity regions had association equilibrium constants that
increased from 4.4 × 104 M−1 to 7.2 × 104 M−1 for the same columns.
The binding of glibenclamide to normal HSA and glycated HSA at Sudlow sites I and II and
at the digitoxin site was confirmed through the use of zonal elution competition studies. The
affinities for glibenclamide at Sudlow sites I and II of normal HSA were 2.4 × 104 M−1 and
3.9 × 104 M−1, respectively. These values were consistent with values that were estimated
for the lower affinity sites in the frontal analysis experiments. As the level of glycation was
increased, a 1.7- to 1.9-fold increase in affinity was seen for glibenclamide at Sudlow site I
for HSA with moderate to high levels of glycation. An even larger change was noted at
Sudlow site II, in which an increase in affinity of 4.3- to 6.0-fold was observed versus
normal HSA for all of the tested glycated HSA samples. The association equilibrium
constant for glibenclamide at the digitoxin site of normal HSA was 2.1 × 106 M−1, which fit
with the value that was measured for the high affinity sites by frontal analysis. Further
studies indicated that glycation may have lead to a slight decrease in affinity for
glibenclamide at the digitoxin site, but this change was not significant at the 95% confidence
level for any individual sample of glycated HSA.
The results of this report are of clinical interest for several reasons. First, the large changes
in binding seen for glibenclamide with glycated HSA, especially at Sudlow site II, are of
clinical interest because they would be expected to alter the affective dose of the drug by
changing the drug’s free fraction in the circulation. This effect is of potential importance for
sulfonylurea drugs like glibenclamide because of the high level of plasma protein binding of
this drug, the relatively narrow therapeutic range of this drug in serum, and the undesirable
effects that occur if such the apparent activity of this drug levels fall below or above this
range (i.e., hyperglycemia or hypoglycemia) [9–11]. The fact that the major drug binding
regions on HSA are affected to different extents by glycation is also of interest in that it
implies that drug-drug interactions at these sites will also vary for agents like glibenclamide.
Finally, this work confirms that many sulfonylurea drugs can bind to Sudlow sites I and II
but also demonstrates for the first time that the digitoxin site can play a major role in these
interactions in the case of glibenclamide.
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These results also illustrate how HPAC can be modified and used for examining the
interactions of relatively non-polar drugs like glibenclamide with modified proteins and to
provide a quantitative analysis of the changes in binding for such drugs that may occur both
globally and at specific interaction sites. These efforts were aided by many of the potential
advantages of HPAC for drug-binding studies. For instance, the ability of HPAC to be used
with detection methods such as UV/visible absorbance spectroscopy [31–33,35,39–42] made
it possible to look at the low-to-moderate concentrations of glibenclamide that were required
for the frontal analysis and zonal elution experiments in this report. The good precision and
fast analysis times of HPAC [31–33], along with the ability to reuse normal HSA or
glycated HSA columns over hundreds of experiments [14–16], made it convenient to use
more replicates and sample concentrations with these columns without the need for
additional protein. Furthermore, this last feature made it possible to use the same protein
preparations as in work with previous sulfonylurea drugs [14–16,58], allowing a direct
comparison to now be made in the binding properties of glibenclamide versus these other
drugs. The ability to easily combine this method with new probes (e.g., digitoxin) for
examining newly-identified drug-protein interaction sites was further illustrated in this
report. The approaches used here for such experiments are not limited to glibenclamide and
HSA but could be adapted for use with systems that involve other drugs or modified
proteins. Based on these features, it is expected that HPAC will continue to grow in
applications and as a powerful technique for examining these and additional types of
biological interactions.
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Highlights
• HPLC affinity columns were used to study drug binding with modified proteins.
• Binding of glibenclamide with glycated human serum albumin (HSA) was
studied.
• Frontal analysis was used to detect global changes in binding for glycated HSA.
• Competition studies examined site-specific changes in binding by
glibenclamide.
• Local changes in binding upon HSA glycation were seen at Sudlow sites I and
II.
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Figure 1.
Structure of glibenclamide. The region within the dashed box shows the core structure of a
sulfonylurea drug.
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Figure 2.
Example of frontal analysis studies for glibenclamide on a normal HSA column at pH 7.4
and 37°C. These results were obtained at 0.5 mL/min and using glibenclamide
concentrations of 50, 20, 10, and 5 μM (top-to-bottom). The small initial step changes
shown to the left occurred at or near the column void time and probably represent only a
small difference in composition and background absorbance of each drug solution versus the
application buffer; these small step changes were not included in the data analysis and
integration of the much larger frontal analysis curves that are shown to the right.
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Figure 3.
Data obtained for glibenclamide on a normal HSA column as fit to (a) a one-site binding
model generated by using Eq. (1) or (b) a two-site binding model generated by using Eq. (3).
The insets in (a) and (b) show the corresponding residual plots. Each point represents the
average of four runs, with typical relative standard deviations that ranged from ±0.02% to
±7.9% (average, ±1.9%).
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Figure 4.
A double-reciprocal plot for frontal analysis experiments that examined the binding of
glibenclamide with normal HSA. The data in this plot were the same as utilized in Figure 3.
The best-fit line was generated by using the data for 0.5–5 μM glibenclamide and gave a
correlation coefficient of 0.996 (n = 7).
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Figure 5.
Plots prepared according to Eq. (6) that show how the reciprocal of the retention factor for
(a) R-warfarin or (b) L-tryptophan changed on normal HSA or glycated HSA columns as the
concentration of glibenclamide was varied in the mobile phase. These results are for normal
HSA (●) and gHSA2 (▲). Each point in these plots is the mean of four runs, with relative
standard deviations in (a) that ranged from ±0.3% to ±2.6 (average, ±2.1%) and in (b) that
ranged from ±2.2% to ±15.4 (average, ±7.1%). The correlation coefficients for the normal
HSA and gHSA2 plots in (a) were 0.966 (n = 6) and 0.975 (n = 8), respectively, while the
correlation coefficients in (b) were 0.970 (n = 7) and 0.993 (n = 8).
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Figure 6.
Plots prepared according to Eq. (6) that show how the reciprocal of the retention factor for
digitoxin on HSA or glycated HSA columns changed as the concentration of glibenclamide
was varied in the mobile phase. These results are for normal HSA (●) and gHSA3 (◆). The
correlation coefficients for these plots were 0.998 (n = 5) and 0.999 (n = 5), respectively.
Each point in these plots is the mean of four runs, with relative standard deviations that
ranged from ±0.6% to ±4.6 (average, ±1.8%).
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Table 1
Association equilibrium constants and moles of binding sites estimated when using a two-site model to
describe the binding of glibenclamide with normal HSA and gHSA3 at pH 7.4 and 37 °Ca
Type of HSAb Ka1 (× 106 M−1) mL1 (× 10−8 mol) Ka2 (× 104 M−1) mL2 (× 10−8 mol)
Normal HSA 1.4 (± 0.5) 1.1 (± 0.2) 4.4 (± 1.0) 3.1 (± 0.1)
gHSA3 1.9 (± 1.5) 0.9 (± 0.3) 7.2 (± 2.8) 2.4 (± 0.2)
a
The values in parentheses represent a range of ±1 S.D., as based on error propagation and the precisions of the best-fit slopes and intercepts
obtained when using Eq. (3) for n = 16.
b
The level of glycation for the gHSA3 sample is given in Section 2.3.
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Table 2
Local association equilibrium constants obtained for glibenclamide at specific binding regions of normal HSA
and glycated HSA at 37°C and pH 7.4a
Type of HSAb
Association equilibrium constant, KaI
Sudlow site I, (× 104 M−1) Sudlow site II (× 104 M−1) Digitoxin site (× 106 M−1)
Normal HSA 2.4 (± 0.3) 3.9 (± 0.2) 2.1 ± (0.8)
gHSA1 2.5 (± 0.1) 16.7 (± 0.4) 1.7 ± (0.8)
gHSA2 4.1 (± 0.7) 23.3 (± 0.8) 1.1 ± (0.4)
gHSA3 4.5 (± 0.3) 17.8 (± 0.4) 1.2 ± (0.2)
a
The values in parentheses represent a range of ±1 S.D., as based on error propagation and the precisions of the best-fit slopes and intercepts
obtained when using Eq. (6) for n = 5–8.
bgHSA1, gHSA2, and gHSA3 refer to glycated HSA samples with different levels of glycation, as described in more detail in Section 2.3.
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